One-stop clinic for assessment of risk of chromosomal defects at 12 weeks of gestation

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 12, Issue 1, 2002, Pages 9-18

  Nicolaides, K H ^a   Bindra, R ^a   Heath, V ^a   Cicero, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chromosomal defects; Free human chorionic gonadotropin; Nuchal translucency; Pregnancy associated plasma protein A; Screening; Trisomy 21; Ultrasonography

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

CHROMOSOME ABERRATION; DISEASE ASSOCIATION; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; MATERNAL AGE; MATERNAL BLOOD; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SECOND TRIMESTER PREGNANCY; TRISOMY 21; ADULT; BLOOD; DOWN SYNDROME; ECHOGRAPHY; FEMALE; HIGH RISK PREGNANCY; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; NECK; PREDICTION AND FORECASTING; PREGNANCY; PRENATAL DEVELOPMENT; SENSITIVITY AND SPECIFICITY; STANDARD;

ADULT; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; NECK; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY, HIGH-RISK; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 0035988786     PISSN: 14767058     EISSN: None     Source Type: Journal    
DOI: 10.1080/jmf.12.1.9.18     Document Type: Review

References (63)

1. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: An observational study
2. Time for total shift to first-trimester screening for Down's syndrome
3. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population based cohort study
4. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation
5. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester
6. Assessment of risks
7. The imprecision in rates of Down syndrome by 1-year maternal age intervals: A critical analysis of rates used in biochemical screening
8. Maternal age and gestational age-specific risks for chromosomal defects
9. Maternal age and gestation-specific risk for trisomy 21
10. New estimates of Down syndrome risks at chorionic villus sampling, amniocentesis, and livebirth in women of advanced maternal age from a uniquely defined population
11. Fetal loss in Down syndrome pregnancies
12. Observations on an ethnic classification of idiots
13. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy
14. The implementation of first-trimester scanning at 10-13 weeks' gestation and the measurement of fetal nuchal translucency thickness in two maternity units
15. First-trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age
16. Increased nuchal translucency as a marker for fetal chromosomal defects
17. Results of routine fetal nuchal translucency measurement at 10-13 weeks in 4,233 unselected pregnant women
18. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population
19. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
20. First trimester sonographic detection of chromosomal abnormalities in an unselected population
21. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population
22. Evaluation of first-trimester screening by fetal nuchal translucency and maternal age
23. Fetal nuchal translucency screening in 12 495 pregnancies in Sardinia
24. Screening for trisomy 21 by fetal nuchal translucency and maternal age: A multicenter project in Germany, Austria and Switzerland
25. First-trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population
26. Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: A prospective longitudinal study
27. Four years experience of first-trimester nuchal translucency screening for fetal aneuploidies with increasing regional availability
28. Nuchal translucency and chromosomal defects
29. Prenatal diagnosis of trisomy 18 at the 10-14-week ultrasound scan
30. Increased nuchal translucency in trisomy 13 fetuses at 10-14 weeks of gestation
31. Detection of sex chromosome abnormalities by nuchal translucency screening at 10-14 weeks
32. Early prenatal diagnosis of triploidy
33. Nuchal translucency measurement: Training of potential examiners
34. Repeatability of measurement of fetal nuchal translucency thickness
35. The effect of fetal neck position on nuchal translucency measurement
36. Nuchal translucency measurements: Frequency distribution and changes with gestation in a general population
37. The effect of nuchal cord on nuchal translucency measurement at 10-14 weeks
38. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice
39. First trimester nuchal translucency screening of the general population: Data from three centres
40. First trimester fetal nuchal translucency: Problems with screening the general population. 1
41. Results of measurement of nuchal translucency before and after training
42. Appropriate biochemical parameters in first-trimester screening for Down syndrome
43. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A
44. First trimester Down syndrome screening: Free β-human chorionic gonadotropin and pregnancy associated plasma protein A
45. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy
46. Screening for Down's syndrome: Changes in marker levels and detection rates between first and second trimester
47. Screening of maternal serum for fetal Down's syndrome in the first trimester
48. Prenatal screening in the first trimester of pregnancy
49. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency
50. First-trimester screening for aneuploidy: Biochemistry and nuchal translucency
51. Maternal serum screening for Down syndrome in the first trimester: Experience from Belarus
52. Maternal serum pregnancy associated placental protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy
53. Maternal serum hCG and fetal nuchal translucency thickness for the prediction of fetal trisomies in the first trimester of pregnancy
54. First trimester screening for Down's syndrome using nuchal translucency measurement with free β-hCG and PAPP-A between 10 and 13 weeks of pregnancy: The combined test
55. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation
56. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG and PAPP-A at 10-14 weeks of gestation
57. Maternal serum free beta hCG and PAPP-A in fetal sex chromosome defects in the first trimester
58. Screening for triploidy by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation
59. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters
60. Prenatal screening for Down's syndrome - A search for the family's values
61. The effect of nuchal translucency measurement on second trimester biochemical screening for Down's syndrome
62. Effect of first-trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome
63. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population